These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29913476)

  • 1. A new amphetamine oral suspension (Adzenys ER) for ADHD.
    Med Lett Drugs Ther; 2018 Jun; 60(1549):e106-e108. PubMed ID: 29913476
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs for ADHD.
    Med Lett Drugs Ther; 2020 Jan; 62(1590):9-15. PubMed ID: 31999670
    [No Abstract]   [Full Text] [Related]  

  • 3. Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD.
    Frampton JE
    Drugs; 2018 Jul; 78(10):1025-1036. PubMed ID: 29923015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
    Pozzi M; Carnovale C; Mazhar F; Peeters GGAM; Gentili M; Nobile M; Radice S; Clementi E
    J Clin Psychopharmacol; 2019; 39(4):386-392. PubMed ID: 31205193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quillivant XR--an extended release oral suspension of methylphenidate.
    Med Lett Drugs Ther; 2013 Feb; 55(1409):10-1. PubMed ID: 23381227
    [No Abstract]   [Full Text] [Related]  

  • 7. [New-onset trichotillomania during treatment with stimulant drugs. About two pediatric clinical cases].
    Fernández Manso B; Villora Morcillo N; Taboas Pereira MA; Elipe Maldonado C
    Arch Argent Pediatr; 2020 Feb; 118(1):e61-e62. PubMed ID: 31984712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lisdexamfetamine: A Review in ADHD in Adults.
    Frampton JE
    CNS Drugs; 2016 Apr; 30(4):343-54. PubMed ID: 27048350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated 2018 NICE guideline on pharmacological treatments for people with ADHD: a critical look.
    Faltinsen E; Zwi M; Castells X; Gluud C; Simonsen E; Storebø OJ
    BMJ Evid Based Med; 2019 Jun; 24(3):99-102. PubMed ID: 30530806
    [No Abstract]   [Full Text] [Related]  

  • 10. Lisdexamfetamine.
    Blick SK; Keating GM
    Paediatr Drugs; 2007; 9(2):129-35; discussion 136-8. PubMed ID: 17407369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges.
    López FA; Leroux JR
    Atten Defic Hyperact Disord; 2013 Sep; 5(3):249-65. PubMed ID: 23564273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic and exposure-response analyses of d-amphetamine after administration of lisdexamfetamine dimesylate in Japanese pediatric ADHD patients.
    Tsuda Y; Matsuo Y; Matsumoto S; Wajima T
    Drug Metab Pharmacokinet; 2020 Dec; 35(6):548-554. PubMed ID: 33082099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lisdexamfetamine dimesylate: a Treatment Option for Children and Adolescents with Attention Deficit/Hyperactivity Disorder in Germany and Across Europe].
    Häge A; Banaschewski T; Dittmann RW
    Fortschr Neurol Psychiatr; 2015 Dec; 83(12):676-85. PubMed ID: 26714249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Banaschewski T; Johnson M; Nagy P; Otero IH; Soutullo CA; Yan B; Zuddas A; Coghill DR
    CNS Drugs; 2018 May; 32(5):455-467. PubMed ID: 29790103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylphenidate Overdose Causing Secondary Polydipsia and Severe Hyponatremia in an 8-Year-Old Boy.
    Patel V; Krishna AS; Lefevre C; Kaagaza M; Wittkamp M
    Pediatr Emerg Care; 2017 Sep; 33(9):e55-e57. PubMed ID: 27115479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Duration of Effect of Open-Label Lisdexamfetamine Dimesylate in Adults With ADHD.
    Adler LA; Lynch LR; Shaw DM; Wallace SP; O'Donnell KE; Ciranni MA; Briggie AM; Faraone SV
    J Atten Disord; 2017 Jan; 21(2):149-157. PubMed ID: 23657761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.
    Coghill DR; Banaschewski T; Nagy P; Otero IH; Soutullo C; Yan B; Caballero B; Zuddas A
    CNS Drugs; 2017 Jul; 31(7):625-638. PubMed ID: 28667569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azstarys (serdexmethylphenidate/dexmethylphenidate) for ADHD.
    Med Lett Drugs Ther; 2021 Oct; 63(1634):157-159. PubMed ID: 34550957
    [No Abstract]   [Full Text] [Related]  

  • 19. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.
    Setyawan J; Yang H; Cheng D; Cai X; Signorovitch J; Xie J; Erder MH
    Value Health; 2015 Sep; 18(6):824-31. PubMed ID: 26409610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.